Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibition of HDAC attenuates VEGF signalling, which is important for vascular morphogenesis and endothelial differentiation [195].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [195]
Citations
Cites
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 7×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 4×
“HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing.”
BackgroundInfluentialAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Antiangiogenic therapy of cancers o ers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997).”
BackgroundA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 2×
“By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in di erent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis.”
BackgroundMethodSelf-citationHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 7×
“At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001).”
BackgroundMethodInfluentialKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps
Vittet, D., Prandini, M., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., & Dejana, E. (1996) · Blood · doi:10.1182/blood.v88.9.3424.bloodjournal8893424 · Cited by 472 · cited 1×
“Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996).”
MethodNeuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458 · cited 5×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialDeroanne, C. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00233-9 · Cited by 256 · cited 1×
“Culture medium, Oncogene HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996, 2001).”
MethodSelf-citation
Cited by
Items 201–300 of 406
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
Wong, N.-S., Seah, E., Wang, L., Yeo, W.-L., Yap, H., Chuah, B., Lim, Y.-W., Ang, P., Tai, B., Lim, R., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a8639 · Cited by 40
You, D., Richardson, J. R., & Aleksunes, L. M. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089953 · Cited by 41
“genes and repression of proangiogenic genes (Kim et al., 2001; Deroanne et al., 2002; Kwon et al., 2002).”
BackgroundEpigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suárez-Álvarez, B. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01168-5 · Cited by 41
Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Krause, B., Sobrevia, L., & Casanello, P. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109789043883 · Cited by 40
Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity
Zecchin, A., Pattarini, L., Gutierrez, M. I., Mano, M., Mai, A., Valente, S., Myers, M. P., Pantano, S., & Giacca, M. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju010 · Cited by 37
“The apparent contradiction between the use of KDACi to inhibit tumor angiogenesis and our novel findings linking VEGFR2 hyperacetylation with increased receptor activation might be partially explained by the fact that prolonged deacetylases inhibition has a major impact on gene expression, rather than on the fine tuni…”
BackgroundInfluentialPanobinostat for the treatment of multiple myeloma
Neri, P. E., Bahlis, N. J., & Lonial, S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668883 · Cited by 40
“transcription factor HIF-1a enhancing its degradation [20,39] and decrease the production of the vascular endothelial growth factor receptor (VEGFR) [40], increasing the formation of the intracellular reactive oxygen species and, therefore, impairing cell chemotaxis and invasion [41].”
BackgroundHrgović, I., Doll, M., Pinter, A., Kaufmann, R., Kippenberger, S., & Meißner, M. (2016) · Experimental Dermatology · doi:10.1111/exd.13159 · Cited by 38
Radiosensitizing Potential of Epigenetic Anticancer Drugs
Schutter, H. D., & Nuyts, S. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787047707 · Cited by 41
Takada, M., Fujimoto, M., Motomura, H., & Hosomi, K. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.13834 · Cited by 37
“HDACs play important roles in transcriptional regulation and pathogenesis of cancer and have also been shown to downregulate angiogenesis-related gene expression in endothelial and tumor cells [28, 29].”
BackgroundTanaka, N., Patel, A. A., Tang, L., Silver, N. L., Lindemann, A., Takahashi, H., Jaksik, R., Rao, X., Kalu, N. N., Chen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0947 · Cited by 39
“Consistent with published results (36, 37), we show that the fraction of cells with vasculature marker CD31 is decreased following vorinostat alone or in combination with AZD1775, supporting our previous finding that disruption of the tumor microvasculature can contribute to antitumor efficacy in HNSCC (47).”
Ogawa, H., Rafiee, P., Fisher, P. J., Johnson, N. A., Otterson, M. F., & Binion, D. G. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01110-4 · Cited by 39
Liu, Y., Tong, Y., Yang, X., Li, F., Zheng, L., Liu, W., Wu, J., Ou, R., Zhang, G., Hu, M., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.028 · Cited by 36
Lindberg, D. M., Åkerström, G., & Westin, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03034.x · Cited by 34
Fouliard, S., Robert, R., Jacquet-Bescond, A., du Rieu, Q. C., Balasubramanian, S., Loury, D. J., Loriot, Y., Hollebecque, A., Kloos, I., Soria, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.009 · Cited by 34
Cavasin, M. A., Stenmark, K. R., & McKinsey, T. A. (2015) · Pulmonary Circulation · doi:10.1086/679700 · Cited by 34
“Indeed, HDAC inhibitors have been shown to elicit antiangiogenic effects through suppression of VEGF signaling in cancer models.(77,78) To provide mechanistic insight into the observed reduction in RV capillary density, the authors performed in vitro studies with cultured human”
HDAC inhibition upregulates the expression of angiostatic ADAMTS1
Chou, C., & Chen, C. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.048 · Cited by 37
ARDent about acetylation and deacetylation in hypoxia signalling
Bilton, R. L., Trottier, E., Pouysségur, J., & Brahimi-Horn, M. C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.002 · Cited by 38
Li, X., Zhou, Q., Hanus, J., Anderson, C. A., Zhang, H., Dellinger, M. T., Brekken, R. A., & Wang, S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300445a · Cited by 32
Stratton, M. S., & McKinsey, T. A. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0119 · Cited by 33
“Indeed, HDAC inhibitors have been shown to elicit anti-angiogenic effects through suppression of VEGF signaling in cancer models (Deroanne et al. 2002; Mottet and Castronovo 2010).”
BackgroundSaha Suppresses Peritoneal Fibrosis in Mice
Io, K., Nishino, T., Obata, Y., Kitamura, M., Koji, T., & Kohno, S. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2013.00089 · Cited by 33
“It has been also reported that SAHA suppressed inflammation and angiogenesis (18,19).”
BackgroundPharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy
Claes, B., Buysschaert, I., & Lambrechts, D. (2010) · Heredity · doi:10.1038/hdy.2010.42 · Cited by 37
“For instance, the HDAC inhibitor TSA impairs blood vessel formation in vitro and in vivo by downregulating pro-angiogenic signaling factors, such as the vascular endothelial growth factor (VEGF) and by upregulating angiostatic factors, such as ADAMTS-1 (Deroanne et al., 2002; Rossig et al., 2002; Chou and Chen, 2008).”
Singh, B. N., Zhou, H., Li, J., Tipton, T., Wang, B., Shao, G., Gilbert, E. N., Li, Q., & Jiang, S. (2011) · Future Oncology · doi:10.2217/fon.11.124 · Cited by 30
Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
Chan, N., He, S., Spee, C. K., Ishikawa, K., & Hinton, D. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120587 · Cited by 31
“studied TSA’s and SAHA’s anti-angiogenic effect in various angiogenesis assays, and established that TSA down-regulated the expression of the VEGF receptors in HUVECs [57].”
BackgroundValproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals
Zhao, Y., You, W., Zheng, J. J., Chi, Y., Tang, W., & Du, R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1494-0 · Cited by 30
“Recent studies indicated that HDACIs such as FK228 can inhibit the expression of angiogenic factors, including VEGF and basic fibroblast growth factor (bFGF), and therefore suppress the angiogenesis of cancer cells [12, 14, 15].”
BackgroundToxicity study of ochratoxin A using HEK293 and HepG2 cell lines based on microRNA profiling
Zhao, J., Qi, X., Dai, Q., He, X., Dweep, H., Guo, M., Luo, Y., Gretz, N., Luo, H., Huang, K., et al. (2016) · Human & Experimental Toxicology · doi:10.1177/0960327116632048 · Cited by 31
Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment
Berndsen, R. H., Abdul, U. K., Weiss, A., Zoetemelk, M., Winkel, M. T. T., Dyson, P. J., Griffioen, A. W., & Nowak-Sliwinska, P. M. (2017) · Angiogenesis · doi:10.1007/s10456-017-9551-z · Cited by 30
The epigenome as a potential mediator of cancer and disease prevention in prenatal development
Kaur, P., Shorey‐Kendrick, L. E., Ho, E., Dashwood, R. H., & Williams, D. E. (2013) · Nutrition Reviews · doi:10.1111/nure.12030 · Cited by 29
Goldstein, L. J., Zhao, F., Wang, Μ., Swaby, R. F., Sparano, J. A., Meropol, N. J., Bhalla, K. N., Pellegrino, C. M., Alpaugh, R. K., Falkson, C. I., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4310-9 · Cited by 29
“Both SAHA and trastuzumab have also been shown to inhibit vascular endothelial growth factor levels and exert antiangiogenic effects [25, 26].”
BackgroundA review of epigenetic regulation in wound healing: Implications for the future of wound care
Lewis, C. J., Stevenson, A. W., Fear, M. W., & Wood, F. M. (2020) · Wound Repair and Regeneration · doi:10.1111/wrr.12838 · Cited by 30
Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome: An Overview
Eglen, R. M., & Reisine, T. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111417871 · Cited by 29
“The anticancer actions of HDAC inhibitors have also been linked to their anti-angiogenic effects, which have been linked to their abilities to reduce vascular endothelial growth factor and endothelial nitric oxide synthase expression.(78) They also produce antimetastatic effects by upregulating expression of metastati…”
BackgroundTargeting Histone Deacetylases: Development of Vorinostat for the Treatment of Cancer
Richon, V. M. (2010) · Epigenomics · doi:10.2217/epi.10.20 · Cited by 29
RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer
Yu, Y., Chen, L., Zhao, G., Li, H., Guo, Q., Zhu, S., Li, P., Min, L., & Zhang, S. (2019) · Oncogene · doi:10.1038/s41388-019-1060-7 · Cited by 28
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer
Song, Y., Shiota, M., Tamiya, S., Kuroiwa, K., Naito, S., & Tsuneyoshi, M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03797.x · Cited by 27
Huang, W., Tang, Y.-A., Chen, M., Wang, Y.-J., Hu, F.-H., Wang, T.-W., Chao, S.-W., Chiu, H., Yeh, Y.-L., Chang, H., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.016 · Cited by 27
“Reports have indicated that some HDAC inhibitors such as SAHA and LBH589 decrease the expression of several pro-angiogenic factors, including vascular endothelial growth factor and hypoxia-inducible factor-1a [38].”
BackgroundJones, A., Lechner, M., Fourkala, E.-O., Kristeleit, R. S., & Widschwendter, M. (2010) · Epigenomics · doi:10.2217/epi.09.47 · Cited by 28
Vascular endothelial-derived semaphorin 3 inhibits sympathetic axon growth
Damon, D. H. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01232.2004 · Cited by 27
Histone deacetylase (HDACs) inhibitors: Clinical applications
Shanmukha, K. D., Paluvai, H., Lomada, S. K., Gokara, M., & Kalangi, S. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.011 · Cited by 29
CASTRONOVO, V., Peixoto, P., Bellahcène, A., & Turtoï, A. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014012423 · Cited by 30
Self-citationQuinn, D. I., Tsao-Wei, D. D., Twardowski, P. W., Aparicio, A. M., Frankel, P. H., Chatta, G. S., Wright, J. J., Groshen, S. G., Khoo, S., Lenz, H., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01038-6 · Cited by 27
“VEGF VEGF and other angiogenesis factors overexpressed [11] [38] VEGFR expression decreased [39]”
BackgroundSeité, S., Colige, A., Deroanne, C., Lambert, C., Piquemal-Vivenot, P., Montastier, C., Fourtanier, A., Lapière, C., & Nusgens, B. (2004) · Photochemistry and Photobiology · doi:10.1562/yg-03-09.1 · Cited by 26
“Pairs of RT-PCR primers were selected as described previously (14-16).”
MethodSelf-citationPotential use of histone deacetylase inhibitors in cancer therapy
Gołąbek, K., Strzelczyk, J. K., Wiczkowski, A., & Michalski, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2015.51824 · Cited by 26
“It is assumed that HDACi can also have an anti-angiogenic and inhibitory effect on the occurrence of metastasis through modulation of expression of the coding genes VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), HIF-1α (hypoxia-inducible factor-1α), angiopoietins, eNOS (endothelial n…”
BackgroundEpigenetic modulators mitigate angiogenesis through a complex transcriptomic network
Shankar, T. V. S., & Willems, L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.01.003 · Cited by 27
Recent Advances in the Treatment of Malignant Pleural Mesothelioma
Ramalingam, S. S., & Belani, C. P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181834f66 · Cited by 28
Casanello, P. C., Schneider, D., Herrera, E. A., Uauy, R. D., & Krause, B. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00049 · Cited by 25
“DNA methylation In vitro and in vivo progenitor endothelial cells differentiation Activation of tissue-specific genes Ischemia-induced neo-vascularization Chan et al. (2004), Lagarkova et al. (2008), Ohtani et al. (2011), Rao et al. (2011) Histone acetylation Hypoxia-, VEGF- and shear stress- induced angiogenesis VEGF…”
BackgroundInfluentialComparison of Anticancer Effects of Carbamazepine and Valproic Acid
Akbarzadeh, L., Zanjani, T. M., & Sabetkasaei, M. (2016) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.37230 · Cited by 27
“HDACIs regulate the expression of multiple genes that play an important role in tumor progression and angiogenesis (29, 30).”
BackgroundDysregulations of MicroRNA and Gene Expression in Chronic Venous Disease
Zalewski, D. P., Ruszel, K. P., Stępniewski, A., Gałkowski, D., Bogucki, J., Komsta, Ł., Kołodziej, P., Chmiel, P., Zubilewicz, T., Feldo, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051251 · Cited by 25
“Analyzed genes were associated with cardiovascular diseases and risk factors (TBC1D22A, WNK1), bone mineral density (HDAC5), body weight (PABPC3), glycerophospholipid metabolism (CDS2), Notch signaling (HDAC5), RNA transport and degradation (PABPC3).”
ResultInfluentialEpigenetic targeting in breast cancer: Therapeutic impact and future direction
Lustberg, M. B., & Ramaswamy, B. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.7.1405072 · Cited by 27
Komorowsky, C. V., Ocker, M., & Goppelt‐Struebe, M. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00674.x · Cited by 28
“In tumours treated with HDIs, endothelial-derived CTGF may thus contribute to the anti-angiogenic properties of HDIs observed in vivo, similarly as suggested for semaphorin III, a competitor of VEGF-165 binding to neuropilin-1, which was induced by HDIs in endothelial cells [7].”
BackgroundCao, Y., Choy, E., Hornicek, F. J., Wood, K. B., Schwab, J. H., Liu, X., Mankin, H. J., & Duan, Z. (2011) · PubMed · Cited by 24
Acetylation and Histone Deacetylase Inhibitors in Cancer
Kortenhorst, M. S. Q., Carducci, M. A., & Shabbeer, S. (2006) · Analytical Cellular Pathology · doi:10.1155/2006/760183 · Cited by 27
Cyclin-Dependent Kinase 4 (CDK4) Expression in Pancreatic Endocrine Tumors
Lindberg, D. M., Hessman, O., Åkerström, G., & Westin, G. (2007) · Neuroendocrinology · doi:10.1159/000106762 · Cited by 23
Li, X., He, S., & Zhao, M. (2020) · Aging and Disease · doi:10.14336/ad.2019.1126 · Cited by 24
“TSA and other HDACis could not only inhibit endothelial cell proliferation but also downregulate VEGF-receptor expression [36-38].”
BackgroundGao, D., Xia, Q., Lv, J., & Zhang, H. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01823.x · Cited by 22
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma
Wittenburg, L. A., Ptitsyn, A. A., & Thamm, D. H. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23403 · Cited by 22
“…senescence, enhanced apoptosis, decreased angiogenesis, immunomodulatory activities, and an ability to synergize with traditional cytotoxic chemotherapies and radiation [Deroanne et al., 2002; Kim et al., 2003; Bolden et al., 2006; Minucci and Pelicci, 2006; Tomasi et al., 2006; Xu et al., 2007].”
BackgroundHistone Deacetylase Inhibitor Reduces Hypertrophic Scarring in a Rabbit Ear Model
Diao, J., Xia, W., Yi, C., Yang, Y., Zhang, X., Xia, W., Shu, M.-G., Wang, Y., Gui, L., & Guo, S. (2013) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e318290f698 · Cited by 23
Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy
Rahman, R., & Grundy, R. G. (2011) · International Journal of Cancer · doi:10.1002/ijc.26241 · Cited by 22
“It is probable that several mechanisms contribute to HDACiinduced anticancer effects, given the multitude of cellular effects triggered by HDACi; indeed 2–5% of the epigenome may be altered by HDACi.36 The mode of action of a particular HDACi may therefore be dependent on the context of the cell type or tumor in quest…”
BackgroundInfluentialInvestigational Drug Treatments for Triple-Negative Breast Cancer
Damaskos, C., Garmpis, N., Garmpi, A., Nikolettos, K., Sarantis, P., Georgakopoulou, V., Nonni, A., Schizas, D., Antoniou, E., Karamouzis, M. V., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070652 · Cited by 21
Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells
Shim, J. S., Kim, D. H., & Kwon, H. J. (2003) · Oncogene · doi:10.1038/sj.onc.1207289 · Cited by 22
“Gelsolin is an actin-binding protein believed to be involved in HDAC inhibitorinduced morphological changes in tumor cells (Hoshikawa et al., 1994). p53, VHL, and semaphorin III were identified as critical target genes of HDAC-mediated tumor angiogenesis (Kim et al., 2001; Deroanne et al., 2002).”
BackgroundVorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
Sato, A. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s23874 · Cited by 22
“Vorinostat reportedly inhibits angiogenesis by decreasing the expression of the vascular endothelial growth factor (VEGF) receptor and inhibits VEGF-induced angiogenesis.(62) Vorinostat inhibits HDAC6 and this may be another important mechanism of action.”
Chuang, Y., Huang, S., Hsu, Y., Yu, M., Ou, G., Huang, W., & Hsu, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13929 · Cited by 21
“A number of novel hydroxamate derivatives as HDAC inhibitors have been shown to exhibit broad-spectrum anti-tumour activities (Deroanne et al., 2002; Venugopal et al., 2013; Rajak et al., 2014; West and Johnstone, 2014).”
BackgroundMonga, V., Swami, U., Tanas, M. R., Bossler, A., Mott, S. L., Smith, B. J., & Milhem, M. M. (2018) · Cancers · doi:10.3390/cancers10020053 · Cited by 20
“Bevacizumab is a recombinant human monoclonal antibody that binds human VEGF, and has been the most explored agent in various malignancies.”
BackgroundInfluentialAnti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy
Iizuka, N., Morita, A., Kawano, C., Mori, A., Sakamoto, K., Kuroyama, M., Ishii, K., & Nakahara, T. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.10.004 · Cited by 20
Horion, J., Gloire, G., Mjiyad, N. E., Quivy, V., Vermeulen, L., Berghe, W. V., Haegeman, G., Lint, C. M. V., Piette, J. G., & Habraken, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609166200 · Cited by 21
Li, J., Zhang, T., Yang, F., He, Y., Dai, F., Gao, D., Chen, Y., Liu, M., & Yi, Z. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13165 · Cited by 20
“Several HDACs induced angiogenic stimulators and thus increased angiogenesis (Deroanne et al., 2002; Rossig et al., 2002; Sasakawa et al., 2003).”
BackgroundSuberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization
Zhou, H., Jiang, S., Chen, J., & Su, S. B. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0117 · Cited by 20
“…(2014) dx.doi.org/10.1139/cjpp-2014-0117 Published at www.nrcresearchpress.com/cjpp on 26 August 2014. and reduce the expression of angiogensis factor, such as vascular endothelial growth factor (VEGF), and suppress tumor angiogenesis (Deroanne et al. 2002; Jeong et al. 2002; Xu et al. 2007).”
BackgroundInfluentialIordache, F., Buzilă, C. A., Constantinescu, A. A., Andrei, E., & Maniu, H. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131115074 · Cited by 19
“TSA inhibited in a dose-dependent and reversible fashion expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1 [32].”
BackgroundWang, X., Li, G., Wang, A., Zhang, Z., Merchan, J. R., & Halmos, B. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21846 · Cited by 19
“in embryoid bodies and inhibit VEGF-induced angiogenesis [12].”
BackgroundN-Hydroxy-7-(2-naphthylthio) Heptanomide Inhibits Retinal and Choroidal Angiogenesis
Kim, J. H., Kim, J. H., Oh, M., Yu, Y. S., Kim, K.-W., & Kwon, H. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800178b · Cited by 20
Epigenetic Agents in Combined Anticancer Therapy
Kejík, Z., Jakubek, M., Kaplánek, R., Králová, J., Mikula, I., Martasek, P., & Král, V. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0203 · Cited by 19
Hemodynamics mediated epigenetic regulators in the pathogenesis of vascular diseases
Karthika, C. L., Ahalya, S., Radhakrishnan, N., Kartha, C. S., & Surendran, S. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03890-9 · Cited by 18
Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells
Ma, X., Liu, J., Wu, J., Yan, X., Wu, P., Liu, Y., Li, S., Tian, Y., Cao, Y., Chen, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3174 · Cited by 18
Kwak, T. W., Kim, D. H., Chung, C., Lee, H. M., Kim, C. H., Jeong, Y., & Kang, D. H. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/185158 · Cited by 18
Lee, J. K., Ryu, J. K., Yang, K. Y., Woo, S. M., Park, J. K., Yoon, W. J., Lee, S. H., Jeong, K.-S., Kim, Y., & Yoon, Y. B. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182156d5a · Cited by 17
Epigenetic regulation of angiogenesis and its therapeutics
Choi, D. K. (2025) · Genomics & Informatics · doi:10.1186/s44342-025-00038-3 · Cited by 18
Kumanishi, S., Yamanegi, K., Nishiura, H., Fujihara, Y., Kobayashi, K., Nakasho, K., Futani, H., & Yoshiya, S. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4811 · Cited by 18
“Recently, DNMT and HDAC inhibitors were shown to directly inhibit endothelial cell growth and tumor angiogenesis (7,8).”
BackgroundHistone Deacetylase Inhibitors: Novel Agents in Cancer Treatment
Glass, E., & Viale, P. H. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.34-40 · Cited by 17
Zhu, S., Zhu, W., Zhao, K., Yu, J., Lu, W., Zhou, R., Fan, S., Kong, W., Yang, F., & Shan, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01733-4 · Cited by 15
“However, they eventually experience treatment failure due to severe side effects and chemotherapy resistance [54–56].”
BackgroundYang, B., Yu, D., Liu, J., Yang, K., Wu, G., & Liu, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3156-1 · Cited by 16
“HDACIs may also affect tumor cell survival by blocking tumor angiogenesis via HIF-1α and VEGF receptors [17, 18].”
BackgroundMahal, K., Schruefer, S., Steinemann, G., Rausch, F., Schobert, R., Biersack, B., & Höpfner, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2685-z · Cited by 15
“Mechanistically, this antiangiogenic effect of 3a and 3c might involve aberrant VEGF/VEGFR (vascular endothelial growth factor receptor) or the destabilization of the pro-angiogenic transcription factor HIF-1alpha [4, 44, 45] as has been discussed for SAHA.”
BackgroundAssays for pharmacodynamic analysis of histone deacetylase inhibitors
Chung, E. J., Lee, M.-J., Lee, S., & Trepel, J. B. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.2.213 · Cited by 16
“HDACIs, including trichostatin A, SAHA, depsipeptide and valproic acid, have been reported to block angiogenesis in vivo by altering HIF1-α and vascular endothelial growth factor (VEGF) signalling [122-125].”
BackgroundWang, S., Wang, S., Liu, H.-T., Wang, X., Wu, S., Chen, L.-C., & Liu, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.5795 · Cited by 15
Epigenetic Determinants of Cardiovascular Gene Expression: Vascular Endothelium
Man, H. S. J., Yan, M. S., Lee, J. J., & Marsden, P. A. (2016) · Epigenomics · doi:10.2217/epi-2016-0012 · Cited by 16
Barr, M. P., O'Byrne, K. J., Al-Sarraf, N., & Gray, S. G. (2015) · Epigenomics · doi:10.2217/epi.15.51 · Cited by 16
Chang, Y.-F., Hsu, Y.-F., Chiu, P.-T., Huang, W., Huang, S.-W., Ou, G., Sheu, J., & Hsu, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2765 · Cited by 15
Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation
Hutt, D. M., Roth, D., Marchal, C., & Bouchecareilh, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_6 · Cited by 14
HDAC in obesity: A critical insight
Nijhawan, P., Behl, T., Khullar, G., Pal, G., Kandhwal, M., & Goyal, A. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100212 · Cited by 13
Andersen, C. L., Bjørn, M. E., McMullin, M. F., Harrison, C. N., Samuelsson, J., Ejerblad, E., Zweegman, S., Fernandes, S., Bareford, D., Knapper, S., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.04.002 · Cited by 13
Inhibition of angiogenesis by S-adenosylmethionine
Sahin, M. A., Şahın, E., Gümüşlü, S., Erdoğan, A., & Gültekin, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.138 · Cited by 13
“Antiangiogenic therapy of cancers offers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability and low mutational rate of ECs [13,14].”
BackgroundSooraj, D., Xu, D., Cain, J. E., Gold, D. P., & Williams, B. R. G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0890 · Cited by 13
Reynoso-Roldán, A., Roldán, M. L., Cancino‐Díaz, J. C., Rodríguez–Martínez, S., & Cancino-Diaz, M. E. (2012) · Clinical and investigative medicine · doi:10.25011/cim.v35i6.19205 · Cited by 13
“[15] e global inhibition of HDAC activity inhibits angiogenesis and tumour growth by reducing the expression of proangiogenic factors.[16-18] In particular, the levels of HDAC1 are increased in hypoxic conditions, which leads to the decrease of VHL and p53, allowing an accumulation of HIF-1alpha and an increase in VEG…”
CHENG, H.-T., & Hung, W. (2012) · Oncology Reports · doi:10.3892/or.2012.2188 · Cited by 13
“Fourth, SAHA suppresses angiogenesis to attenuates tumor growth in vivo (17).”
Nakao, Y., & Fusetani, N. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00043-5 · Cited by 13
Histone deacetylase inhibitors in multiple myeloma
Deleu, S., Menu, E., Valckenborgh, E. V., Camp, B. V., Fraczek, J., Broek, I. V., Rogiers, V., & Vanderkerken, K. (2009) · Hematology Reports · doi:10.4081/hr.2009.e9 · Cited by 13
Wedel, S., Hudak, L., Seibel, J., Juengel, E., Oppermann, E., Haferkamp, A., & Blaheta, R. A. (2010) · The Prostate · doi:10.1002/pros.21288 · Cited by 12
CHENG, H.-T., & Hung, W. (2013) · Oncology Reports · doi:10.3892/or.2013.2523 · Cited by 12
Borutinskaite, V. V., Magnusson, K., & Navakauskienė, R. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1892-5 · Cited by 12
“eNOS in endothelial cells has been shown to be critical for the anti-angiogenic activity of the HDACI valproic acid [9, 10].”
BackgroundZhou, Y., Luo, Q., Gu, L., Tian, X., Zhao, Y., Zhang, Y., & Wang, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040563 · Cited by 13
Targeted molecular therapy in peripheral T-cell lymphomas
Roncolato, F., Gazzola, A., Zinzani, P. L., Pileri, S. A., Piccaluga, P. P., & for the European T-cell Lymphoma Study Group (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.55 · Cited by 11
Yan, M., Qian, Y.-M., Yue, C.-F., Wang, Z.-F., Wang, B., Zhang, W., Zheng, F.-M., & Liu, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9922 · Cited by 11
Metadata
- Authors
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V.
- Affiliations
- University of Liège (BE)
- University of California, San Francisco (US)
- Corresponding author
- Deroanne, Christophe F
- Venue
- Oncogene
- Published
- 2002-01-17
- Volume
- 21
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2031671750
- Cited by
- 400
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 24 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 20 · 2013: 15 · 2012: 27
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- histone deacetylase inhibitors, trichostatin A, vorinostat, angiogenesis inhibitors, VEGF signaling, VEGF receptors, VEGFR1, VEGFR2, neuropilin-1, human umbilical vein endothelial cells, capillary formation, angiogenesis, chromatin remodeling
- MeSH terms
- Vorinostat, Animals, Aorta, Carrier Proteins, Cells, Cultured, Chick Embryo, Chorion, Endothelium, Vascular, Histone Deacetylases, Humans, Hydroxamic Acids, Lymphokines, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Nerve Tissue Proteins, RNA, Messenger, RNA, Ribosomal, 28S, Umbilical Veins, Blotting, Western, Signal Transduction, Up-Regulation, Endothelial Growth Factors, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Semaphorin-3A, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.